Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:02:06 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:IMGN from 2023-05-03 to 2024-05-02 - 36 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-02-12 07:37U:IMGNNews ReleaseAbbVie Completes Acquisition of ImmunoGen
2024-02-01 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-10 12:00U:IMGNNews ReleaseImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
2023-12-05 06:30U:IMGNNews ReleaseFDA Grants Priority Review of ImmunoGen ¢ € ™s Supplemental Biologics License Application for ELAHERE ‚ ® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
2023-12-01 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-01 13:31U:IMGNNews ReleaseSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROVR, IMGN
2023-11-30 13:46U:IMGNNews ReleaseINVESTOR ALERT: Weiss Law Investigates ImmunoGen, Inc.
2023-11-30 07:30U:IMGNNews ReleaseAbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE ‚ ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
2023-11-02 16:30U:IMGNNews ReleaseImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
2023-11-02 06:30U:IMGNNews ReleaseImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
2023-11-01 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-27 06:30U:IMGNNews ReleaseImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
2023-10-23 08:30U:IMGNNews ReleaseAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
2023-10-19 16:01U:IMGNNews ReleaseImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
2023-09-29 17:00U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-28 07:00U:IMGNNews ReleaseELAHERE ‚ ® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FR Ž ±-Positive Platinum-Resistant Ovarian Cancer
2023-09-18 17:00U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-18 06:30U:IMGNNews ReleaseImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
2023-09-05 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-28 06:30U:IMGNNews ReleaseImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE ‚ ® in Japan
2023-08-01 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-31 06:35U:IMGNNews ReleaseImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
2023-07-27 16:30U:IMGNNews ReleaseImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
2023-07-24 06:30U:IMGNNews ReleaseImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
2023-07-17 16:01U:IMGNNews ReleaseImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
2023-07-03 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-09 03:00U:IMGNNews ReleaseImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
2023-06-04 08:00U:IMGNNews ReleaseELAHERE ‚ ® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FR Ž ±-Positive Platinum-Resistant Ovarian Cancer
2023-06-01 16:30U:IMGNNews ReleaseImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-24 16:30U:IMGNNews ReleaseImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
2023-05-09 16:01U:IMGNNews ReleaseImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares
2023-05-09 06:30U:IMGNNews ReleaseImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
2023-05-04 19:45U:IMGNNews ReleaseImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
2023-05-03 16:01U:IMGNNews ReleaseImmunoGen Announces Proposed Public Offering of Common Stock
2023-05-03 06:30U:IMGNNews ReleaseELAHERE ‚ ® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FR Ž ±-Positive Platinum-Resistant Ovarian Cancer